TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.58nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.35nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.45nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.55nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.96nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.04nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.23nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.38nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.49nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.52nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.61nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.03nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.04nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.05nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.09nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.09nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.28nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.55nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.57nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.69nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.84nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.93nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.14nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.17nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.22nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.24nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.25nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.30nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.34nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.39nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.42nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.45nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.46nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.53nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.55nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.57nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.62nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.63nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.68nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.86nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.88nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.97nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.12nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.19nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.25nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.32nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.33nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.33nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.55nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.64nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair